Urgent Evaluation for Non-Visible Haematuria: Retrospective Cohort Insights
Overview
In a cohort of 525 patients with non-visible haematuria (NVH), urological cancer was diagnosed in 4.8%, predominantly bladder cancer. Age ≥60 years and smoking history were significant risk factors for malignancy, suggesting targeted urgent evaluation may be warranted in these groups.
Background
Non-visible haematuria (NVH) affects approximately 2.5% of the general population and is commonly detected via urine dipstick testing in primary care. The primary clinical concern is to exclude urological cancers such as bladder, kidney, and upper tract urothelial cancers. Current guidelines lack uniform recommendations on which NVH patients require urgent referral, leading to resource challenges in secondary care. This study aimed to identify patient groups who benefit most from urgent assessment and to evaluate the necessity of comprehensive investigations for all NVH referrals.
Data Highlights
Parameter
Value
Total patients
525
Male patients
43.4%
Median age
66 years
History of smoking
47%
Lower urinary tract symptoms (LUTS)
43.2%
Anticoagulation therapy
27%
Previous cancer history
8%
Urological cancer diagnosed
25 (4.8%)
Bladder cancer
20 (3.8%)
Renal cancer
3 (0.6%)
Prostate cancer
2 (0.4%)
Median age in cancer patients
77 years
Median age in non-cancer/benign pathology
65 years
Age cutoff for cancer detection (ROC)
60 years (Sensitivity 92%, Specificity 40.2%)
Urological cancer in smokers
7.3%
Key Findings
Urological cancer was identified in 4.8% of NVH patients, with bladder cancer being the most common (3.8%).
Median age of patients with urological cancer was significantly higher (77 years) compared to those with benign or no pathology (65 years).
Age ≥60 years was the optimal cutoff for detecting urological cancer, yielding 92% sensitivity.
History of smoking was associated with a higher risk of urological cancer (7.3%), with no significant difference between current and ex-smokers.
No significant association was found between urological cancer and presence of LUTS, anticoagulation, antiplatelet therapy, or previous urological cancer history.
Clinical Implications
Urgent evaluation for NVH should be prioritized in patients aged 60 years or older and those with a history of smoking due to their higher risk of urological malignancy. Routine urgent investigations in younger patients without risk factors may be unnecessary, potentially optimizing resource allocation. Comprehensive assessment including imaging and cystoscopy remains essential in high-risk groups to exclude malignancy.
Conclusion
This study supports targeted urgent assessment of NVH patients based on age and smoking history to efficiently identify urological cancers. Tailoring referral pathways may reduce unnecessary investigations and alleviate pressure on secondary care services.
References
NICE Guideline 2015 -- Suspected cancer: recognition and referral
Recent Meta-analysis 2020 -- Diagnostic yield of NVH evaluation
